BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has been granted a U.S. patent for a novel low-dose vaccine delivery system that enhances antibody immune response, with promising applications in various diseases. The proprietary DPX™ technology allows for a potent and sustained immune response, which has shown encouraging results in clinical studies for RSV, with potential for other diseases.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
